Scribe Therapeutics to Participate in Upcoming Investor Conferences in May and June

ALAMEDA, Calif.--(BUSINESS WIRE)--Scribe Therapeutics Inc. (Scribe), a genetic medicines company unlocking the potential of CRISPR to transform human health, today announced that the Company will participate in the following upcoming investor conferences in May and June:

• SVB Securities Biopharma Private Company Connect: Members of management will be available for virtual one-on-one meetings on Wednesday, May 24, 2023 and Thursday, May 25, 2023.
• Stifel 2023 Tailoring Genes: Genetic Medicines Day: Benjamin Oakes, Ph.D., Chief Executive Officer of Scribe, will present a virtual corporate overview on Tuesday, May 30, 2023 at 12:05 p.m. ET.
• Jefferies Healthcare Conference: Benjamin Oakes, Ph.D., Chief Executive Officer of Scribe, will present a corporate overview on Friday, June 9, 2023 at 8:00 a.m. ET in New York, NY. Members of management will also be available for one-on-one meetings.

About Scribe Therapeutics

Scribe Therapeutics is revolutionizing the development of optimized genetic medicines that have the potential to durably treat disease at scale. Our CRISPR by Design™ approach engineers bacterial immune systems into a premier suite of genome editing tools built for unique molecular advantages in activity, specificity and deliverability that translate into safer and more effective genetic therapies. Co-founded by Nobel Prize winner Jennifer Doudna and backed by leading life sciences investors, Scribe is engineering the future of genetic medicine. To learn more, visit www.scribetx.com.